CJC-1295 No DAC IU Per Tick Insulin Syringe Dosing Guide

The most common CJC-1295 no DAC dosing error isn't contamination or injection technique. It's tick-mark misinterpretation. A standard U-100 insulin syringe displays 100 tick marks between 0 and 1.0 mL, each representing 0.01 mL of volume. When you reconstitute a 2 mg vial of CJC-1295 no DAC with 1 mL of bacteriostatic water, you create a solution where every 0.01 mL tick delivers exactly 20 micrograms of peptide. Assuming the vial contains 2,000 micrograms total. The math is straightforward, but the consequences of getting it wrong compound across weeks of administration.

Our team has guided researchers through peptide reconstitution protocols for high-purity compounds like CJC1295 Ipamorelin 5MG 5MG across hundreds of laboratory settings. The gap between precise dosing and guesswork comes down to three factors most peptide guides ignore: syringe calibration verification, reconstitution volume accuracy, and dead-space compensation in the needle hub.

How many IU per tick on an insulin syringe when dosing CJC-1295 no DAC?

On a standard U-100 insulin syringe, each tick mark represents 0.01 mL of volume. If CJC-1295 no DAC is reconstituted at a concentration of 100 IU per mL (achieved by adding 1 mL bacteriostatic water to a vial labelled as containing peptide equivalent to 100 IU total), then each 0.01 mL tick delivers exactly 1 IU of peptide. This calibration applies only when the reconstitution volume matches the vial's stated potency in a 1:100 ratio. Deviation from this standard changes the IU-per-tick value proportionally.

The Featured Snippet tells you the math. But it doesn't address why most researchers still dose incorrectly. The issue isn't the calculation; it's the assumption that all insulin syringes are identical. U-100 syringes (100 units per mL) are the standard, but U-40 syringes (40 units per mL) exist and look nearly identical until you check the barrel calibration. Using a U-40 syringe with U-100 dosing instructions delivers 2.5× the intended dose. A mistake that can render weeks of data unusable. This article covers syringe identification, reconstitution volume verification, the dead-space calculation most protocols omit, and what to do when vial labelling doesn't match standard concentrations.

Understanding CJC-1295 No DAC Reconstitution and Syringe Calibration

CJC-1295 without DAC arrives as a lyophilised powder requiring reconstitution with bacteriostatic water before administration. The peptide is a 30-amino-acid analogue of growth hormone-releasing hormone (GHRH), binding to GHRH receptors to stimulate endogenous growth hormone release. Without the DAC modification, the peptide's half-life shortens to approximately 30 minutes, necessitating frequent dosing. Typically 100–200 micrograms per injection, administered 1–3 times daily.

The critical variable in accurate dosing is reconstitution concentration. If you add 1 mL of bacteriostatic water to a 2 mg (2,000 microgram) vial, you create a 2 mg/mL solution. Each 0.01 mL tick on your U-100 insulin syringe then contains 20 micrograms. To dose 100 micrograms, you'd draw to the 0.05 mL mark (5 ticks). If you instead add 2 mL of water to that same vial, you halve the concentration to 1 mg/mL. Now each tick contains 10 micrograms, and your 100-microgram dose requires 10 ticks. The peptide quantity hasn't changed; the concentration has.

Syringe dead space. The residual volume trapped in the needle hub after plunger depression. Typically ranges from 0.02 to 0.07 mL depending on needle gauge and manufacturer. For a 0.10 mL dose, dead space can represent 20–70% loss if uncompensated. Researchers often overdraw by 0.03–0.05 mL to account for this loss, but doing so without recalculating introduces error. The most reliable mitigation is using low-dead-space syringes designed for insulin administration, which reduce residual volume to less than 0.01 mL.

CJC-1295 No DAC IU Per Tick Insulin Syringe Calculation Methods

The term 'IU per tick' becomes meaningful only when peptide potency is expressed in International Units rather than mass. CJC-1295 no DAC is typically quantified by mass (milligrams or micrograms), not IU, because it lacks a standardised biological assay defining one IU. However, some suppliers label vials in 'IU equivalents' based on proprietary conversion factors. A 5 mg vial might be labelled '500 IU' if the supplier defines 1 IU as 10 micrograms. This labelling is non-standardised and creates confusion.

If your vial states '2 mg (200 IU)', the supplier is defining 1 IU as 10 micrograms. Reconstituting this vial with 2 mL bacteriostatic water yields a 100 IU/mL solution. Exactly matching the U-100 syringe calibration, where each 0.01 mL tick delivers 1 IU. If the same 2 mg vial is labelled '2,000 IU' (defining 1 IU as 1 microgram), reconstitution with 2 mL creates a 1,000 IU/mL solution, and each tick delivers 10 IU. The physical peptide content is identical; only the numerical representation differs.

Our experience working with researchers using compounds like Hexarelin shows the most reliable approach is ignoring IU labelling entirely and working strictly in micrograms. Calculate your target dose in micrograms, determine the peptide concentration in micrograms per mL after reconstitution, then calculate the required volume in mL. Converting that volume to 'ticks' is trivial: multiply mL by 100 to get the number of 0.01 mL increments. A 0.15 mL dose equals 15 ticks on a U-100 syringe, regardless of how the vial was labelled.

Verifying Syringe Type and Avoiding U-40/U-100 Confusion

Insulin syringes are manufactured in two primary calibrations: U-100 (100 units per mL) and U-40 (40 units per mL). U-100 syringes dominate current markets, but U-40 syringes remain in circulation, particularly in veterinary settings. The barrels are visually similar, and both display tick marks. But those marks represent different volumes. On a U-40 syringe, each tick equals 0.025 mL instead of 0.01 mL, meaning a researcher who draws to the '10-tick' mark thinking they're administering 0.10 mL is actually drawing 0.25 mL. A 2.5× overdose.

Verification is straightforward: examine the syringe barrel for printed text stating 'U-100' or '100 units'. If no marking is visible, check the manufacturer packaging. U-100 syringes typically display 100 total units on the barrel; U-40 syringes display 40 total units over the same physical length. When in doubt, use a calibrated micropipette to dispense exactly 0.10 mL of water into the syringe and verify the fluid level aligns with the 10-tick mark. If it aligns with the 4-tick mark instead, you're holding a U-40 syringe.

Dead-space compensation calculations assume syringe type has been verified. If you're compensating for 0.03 mL dead space using a U-40 syringe while believing it's U-100, you'll underdraw your target dose by approximately 60%. This isn't a minor calibration issue. It's a protocol-invalidating mistake. Every new syringe batch should be verified before first use.

CJC-1295 No DAC IU Per Tick Insulin Syringe: Dosing Comparison

Reconstitution volume determines concentration, which determines dose volume. Larger vials allow more flexible concentration adjustments. A 10 mg vial reconstituted with 10 mL yields 1 mg/mL, making 100-microgram doses simple to measure (0.10 mL or 10 ticks). Smaller vials force higher concentrations if you want to preserve multi-dose capability, which increases measurement precision requirements. A 2 mg vial reconstituted with 1 mL creates a 2 mg/mL solution where a 100-microgram dose requires drawing to the 0.05 mL mark (5 ticks). Manageable, but less margin for error than a 10-tick draw.

What If: CJC-1295 No DAC Dosing Scenarios

What If My Vial Label Says '5 mg (500 IU)' — How Many Ticks Per 100 Microgram Dose?

The supplier is defining 1 IU as 10 micrograms. Add 5 mL bacteriostatic water to create a 1 mg/mL (or 100 IU/mL) solution. Each 0.01 mL tick contains 10 micrograms (1 IU). To dose 100 micrograms, draw to the 0.10 mL mark (10 ticks). If you instead add 2.5 mL water, you double the concentration to 2 mg/mL (200 IU/mL), and each tick contains 20 micrograms. Your 100-microgram dose now requires only 5 ticks.

What If I Accidentally Used a U-40 Syringe and Already Dosed Three Times?

You've administered 2.5× your intended dose on each injection. If your protocol called for 100 micrograms per dose (drawn to the 10-tick mark on what you believed was a U-100 syringe), you actually delivered 250 micrograms per dose. CJC-1295 no DAC's short half-life means the peptide clears rapidly, but the cumulative exposure over three doses represents significant protocol deviation. Document the error, switch to verified U-100 syringes immediately, and monitor for any deviation in expected biological response.

What If My Reconstituted Vial Looks Cloudy After Mixing?

CJC-1295 no DAC should form a clear, colourless solution after reconstitution. Cloudiness, particulates, or discolouration indicate protein aggregation, contamination, or degradation. The vial is unusable. Do not attempt to clarify it by heating, centrifuging, or filtering. Discard the vial and reconstitute a fresh one, ensuring bacteriostatic water is stored correctly (refrigerated, sealed, used within 28 days of opening) and the vial is brought to room temperature before adding solvent.

The Unvarnished Truth About Peptide Dosing Precision

Here's the honest answer: most peptide research suffers from dosing error, not because the math is complicated, but because researchers assume vial labels reflect verified content. A vial labelled '5 mg CJC-1295 no DAC' might contain 4.2 mg, 5.8 mg, or. In cases of unscrupulous suppliers. Something other than CJC-1295 entirely. Without a certificate of analysis from an independent laboratory using HPLC-MS verification, you're trusting the supplier's internal quality control, which varies dramatically across the industry. Reconstitution calculations are meaningless if the starting peptide quantity is unknown.

Real Peptides supplies research-grade peptides with exact amino-acid sequencing verified through small-batch synthesis protocols. Every vial ships with third-party purity certification because peptide research demands traceability from synthesis to administration. The 'IU per tick' calculation works only when the numerator (peptide quantity) is accurate. If you're working with a 5 mg vial that actually contains 3.7 mg, every dose you draw is 26% under target, and your entire dataset shifts accordingly. The syringe isn't the weak link in peptide dosing. It's the unverified vial content.

Bacteriostatic Water Volume and Multi-Dose Viability

Reconstituted CJC-1295 no DAC remains stable for 28 days when refrigerated at 2–8°C in bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative. The 28-day window reflects the benzyl alcohol's effective antimicrobial duration, not the peptide's chemical stability. Beyond 28 days, bacterial contamination risk increases exponentially.

Reconstitution volume determines how many doses fit within that window. A 5 mg vial reconstituted with 2 mL yields 2.5 mg/mL concentration. If your protocol requires 200-microgram doses three times daily, you're drawing 0.08 mL per dose, consuming 0.24 mL daily, exhausting the vial in 8.3 days. The same vial reconstituted with 5 mL (creating 1 mg/mL concentration) requires 0.20 mL per dose, consuming 0.60 mL daily, exhausting the vial in 8.3 days identically.

Larger reconstitution volumes offer one advantage: reduced dead-space loss as a percentage of total dose. If syringe dead space is 0.03 mL and your dose is 0.05 mL, you lose 60% of the drawn peptide. If your dose is 0.20 mL, dead space represents only 15% loss. Researchers working with limited peptide supplies often choose higher concentrations to minimise waste, accepting reduced measurement margin. Low-dead-space syringes mitigate this tension by reducing residual volume to under 0.01 mL.

The information in this article is for educational purposes. Reconstitution protocols, dosing calculations, and peptide handling should align with institutional biosafety guidelines and be performed under appropriate research oversight.

FAQ Section

Q: How do I calculate the correct number of ticks for my CJC-1295 no DAC dose?
A: Divide your target dose in micrograms by the peptide concentration in micrograms per mL. This gives you the dose volume in mL. Multiply that volume by 100 to convert to ticks on a U-100 syringe. Example: 150 mcg dose ÷ 2,000 mcg/mL concentration = 0.075 mL × 100 = 7.5 ticks. Round to the nearest half-tick if your syringe allows, or round up to 8 ticks to ensure full dosing.

Q: Can I use the same insulin syringe for multiple peptide types?
A: No. Each peptide should be drawn with a fresh, sterile syringe to prevent cross-contamination and ensure accurate dosing. Reusing syringes. Even for the same peptide. Introduces bacterial contamination risk and dulls the needle, increasing injection discomfort and reducing measurement precision. Insulin syringes are single-use devices; dispose of them in a sharps container immediately after administration.

Q: What happens if I store reconstituted CJC-1295 no DAC at room temperature instead of refrigerating it?
A: Peptide degradation accelerates dramatically above 8°C. At room temperature (20–25°C), CJC-1295 no DAC loses approximately 10–15% potency per week through oxidation and deamidation of susceptible amino acids. After 7 days at room temperature, your peptide may retain only 85% of its original activity; after 14 days, 70%. Refrigeration at 2–8°C slows degradation to less than 2% per week, preserving potency across the standard 28-day bacteriostatic water window.

Q: How do I know if my bacteriostatic water is still effective after opening?
A: Bacteriostatic water remains antimicrobially effective for 28 days after first puncture when stored at 2–8°C in its original sealed vial. Beyond 28 days, benzyl alcohol concentration drops below the threshold required to inhibit bacterial growth, even if the solution appears clear. Date your vial upon first use and discard it at day 28 regardless of remaining volume. Cloudiness, particulates, or discolouration before 28 days indicate contamination. Discard immediately.

Q: What is the difference between CJC-1295 with DAC and without DAC in terms of dosing frequency?
A: CJC-1295 with DAC (Drug Affinity Complex) has an extended half-life of approximately 6–8 days due to albumin binding, allowing once- or twice-weekly dosing at 1–2 mg per injection. CJC-1295 without DAC has a half-life of approximately 30 minutes, requiring dosing 1–3 times daily at 100–200 micrograms per injection to maintain stable serum levels. The total weekly peptide quantity may be similar, but the pharmacokinetic profile differs fundamentally. Without DAC produces pulsatile GH release mimicking physiological patterns; with DAC produces sustained elevation.

Q: Can I mix CJC-1295 no DAC with other peptides in the same syringe?
A: Mixing peptides in the same syringe is not recommended unless you have documented evidence of chemical compatibility between those specific compounds. Peptides can interact through disulfide bond formation, aggregation, or pH-mediated degradation when combined in solution. CJC-1295 no DAC is frequently co-administered with ipamorelin or other GHRP peptides in research protocols, but those peptides should be drawn into separate syringes and injected sequentially at different sites to preserve individual peptide integrity and allow independent dose adjustments.

Q: How do I verify my insulin syringe is U-100 and not U-40?
A: Check the syringe barrel for printed text stating 'U-100' or '100 units'. U-100 syringes display 100 numbered units between 0 and 1.0 mL; U-40 syringes display 40 units over the same barrel length. If markings are unclear, dispense exactly 0.10 mL water using a calibrated pipette into the syringe. On a U-100 syringe, the fluid level should align with the 10-unit mark; on a U-40 syringe, it aligns with the 4-unit mark.

Q: What should I do if I draw air bubbles into my peptide dose?
A: Tap the syringe barrel gently with your finger while holding it vertically (needle pointing up) to coalesce small bubbles toward the needle hub. Depress the plunger slowly to expel air until peptide solution reaches the needle tip, then redraw to your target volume. Air bubbles displace peptide volume. A 0.10 mL draw containing 0.02 mL air delivers only 0.08 mL peptide (80% of intended dose). Expelling air after drawing ensures accurate dosing but increases dead-space loss; compensate by overdrawing slightly before bubble removal.

Q: Can I travel with reconstituted CJC-1295 no DAC?
A: Yes, but temperature control is critical. Reconstituted peptide must remain at 2–8°C continuously. Use a medical-grade cooler with verified temperature stability or an insulin travel case designed for pharmaceutical cold-chain transport. TSA guidelines permit medically necessary liquids exceeding 3.4 oz when declared at security, but you should carry documentation (research protocol summary or institutional letter) explaining the peptide's research purpose. Temperature excursions above 8°C for more than 2–4 hours can cause irreversible peptide degradation.

Q: How long does lyophilised CJC-1295 no DAC remain stable before reconstitution?
A: Lyophilised (freeze-dried) CJC-1295 no DAC stored at −20°C remains stable for 24–36 months when sealed and protected from moisture. At 2–8°C (refrigerated but not frozen), shelf life reduces to approximately 12–18 months. At room temperature, degradation accelerates. Expect 50% potency loss within 6–12 months. Always store unopened vials at −20°C or below and avoid repeated freeze-thaw cycles, which cause moisture condensation inside the vial and accelerate peptide breakdown.

Q: What concentration should I target when reconstituting CJC-1295 no DAC for a research protocol?
A: Target concentration depends on dose volume preferences and measurement precision requirements. For 100–200 microgram doses, a 1 mg/mL concentration (achieved by adding 5 mL bacteriostatic water to a 5 mg vial) allows easy measurement (0.10–0.20 mL per dose, or 10–20 ticks). For smaller doses or limited bacteriostatic water supply, a 2 mg/mL concentration works well. Concentrations above 5 mg/mL increase viscosity and injection discomfort; concentrations below 0.5 mg/mL waste bacteriostatic water and increase dead-space loss.

Q: Should I aspirate before injecting CJC-1295 no DAC subcutaneously?
A: Aspiration (pulling back on the plunger after needle insertion to

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

1. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
5. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286